Laekna Therapeutics Raised $61M in Series-D Financing

Laekna Therapeutics, a Shanghai-based biotech company that specializes in clinical-stage biotechnology has raised $61M through Series D funding.

The round was managed by CS Capital and included participation from Yanchuang Capital (Infinity Capital), Worldstar, Yanchuang Capital.

Laekna’s CEO, Dr. Chris Lu is committed to the development of next-generation drugs to treat liver disease and cancer. Laekna has a platform that has allowed the rapid development 14 new drug candidates. Six clinical programs were initiated by the company. Three of these are multi-regional trials (including one pivotal) that address urgent medical needs in the standard care-resistant forms of cancer.

The funds will be used by the company to speed up its development efforts. Proceeds from the Series D financing will be used to accelerate the clinical development of Laekna’s two core product candidates, AKT kinase inhibitor afuresertib (LAE002) and the world’s first clinical-stage CYP17/CYP11B2 dual inhibitor (LAE001). These product candidates are able to target therapy, hormonal therapy, or immuno-oncology therapy. Its most advanced clinical trial is an open-label, randomized, multi-regional Phase 2 PROFECTA-II clinical trial of afuresertib, the world’s first registration-directed clinical trial of an AKT kinase inhibitor to treat platinum-resistant ovarian cancer.

Get latest news from African Startup ecosystem

Latest stories

You might also like...